Identifying Diagnostic Markers in Patients with Metastatic Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study examines blood and tissue samples from patients with metastatic cancer undergoing tumor removal to identify diagnostic markers and potential therapeutic targets. It focuses on analyzing DNA and protein changes in biopsies and tumors to understand the molecular mechanisms of malignancies. By integrating genomic data, the study aims to discover pathways involved in tumor progression and assess the effectiveness of targeted individualized therapies based on these findings. The research involves collecting samples before or after standard care procedures and reviewing patients' medical records.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients (or the legally authorized representative/guardian signing on behalf of the participant) must understand and provide written informed consent prior to initiation of any study-specific procedures
* \>= 18 years of age
* Patients must have a diagnosis of confirmed malignancy
* Patient is a good medical candidate for a standard of care biopsy or surgical procedure to obtain tissue or has archival tissue available for analysis

Exclusion Criteria:

* Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent
* Inaccessible tumor for biopsy or patient does not have tumor tissue available for research use
* Biopsy must not be considered to be more than minimal risk to the patient. Contraindications to percutaneous biopsy:

  * Significant coagulopathy that cannot be adequately corrected
  * Severely compromised cardiopulmonary function or hemodynamic instability
  * Lack of a safe pathway to the lesion
  * Inability of the patient to cooperate with, or to be positioned for, the procedure

Where it's running

• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Aaron S. Mansfield, M.D. — Mayo Clinic in Rochester

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Group sessions to help cancer patients manage stress

  This study is testing if group sessions that teach cancer patients how to manage stress can help them feel better mentally and cope with their treatment.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06015932

• Adding targeted GRID-style radiation to standard palliative therapy for unresectable solid tumors

  This study tests whether adding spatially fractionated radiation therapy to standard palliative radiation helps relieve symptoms in patients with unresectable solid tumors.

  Recruiting at 2 sites Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT07856394

• BMS-986504 plus pemetrexed for MTAP-deleted metastatic solid tumors

  This study tests whether the combination of BMS-986504 and pemetrexed is safe and potentially effective for people with MTAP-deleted metastatic solid tumors.

  Recruiting Phase 1/2 Northwestern University · Chicago, Illinois · NCT07594626

• Morning versus afternoon immunotherapy for advanced or metastatic solid tumors

  This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT07405086

• Virtual reality to reduce psychological symptom burden during cancer treatment

  This trial will try virtual reality sessions to reduce anxiety, depression, and adjustment symptoms for adults receiving cancer treatment.

  Recruiting Mayo Clinic · Jacksonville, Florida · NCT07221409

• TR-002 (Nadofaragene Firadenovec) given by IV for adults with advanced unresectable or metastatic solid tumors and refractory metastatic pancreatic adenocarcinoma

  This Phase 1 trial tests whether weekly intravenous TR-002 is safe and what dose is best for adults with advanced unresectable or metastatic solid tumors or refractory metastatic pancreatic cancer.

  Recruiting Phase 1 University of California, Davis · Sacramento, California · NCT07189195

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.